Crossing the Digital Chasm: Site Burden Isn’t an Excuse Anymore
“If it’s not written down, it didn’t happen.” In clinical research, that phrase is doctrine.
Documentation is the backbone of compliance, audit readiness, and patient safety. For decades, we’ve relied on manual processes to create that proof: handwritten notes, transcribed data, scanned documents, email threads, and spreadsheets.
Those processes built the industry. But they weren’t built for the speed, complexity, and data demands of modern trials, and continuing to rely on them is slowing us down.
It’s clear that using paper simply doesn’t work at scale and as a natural result, many sites and sponsors have turned to technology solutions as a way to reduce administrative burden.
However, using technology to manage clinical trial studies has created a paradox. While digital tools are designed to make trials faster and easier, the sheer volume and fragmentation of these tools has, in fact, created more site burden.
According to findings in Florence Healthcare’s 2026 State of Clinical Trial Technology Report, the majority of clinical trial study sites report using 3 to 9-plus internal systems daily alongside 3 to 9-plus study-specific systems per trial.1
This technology sprawl creates operational friction, with 64% of sites reporting that sponsor-provided technology duplicates their workflows, forcing parallel documentation and manual reconciliation.
The result is that the majority of sites report that technology does not make a positive impact on start-up time and staff efficiency (FIGURE 1).
However, there is another side to the story.
A clear divide is emerging between sites that treat digital infrastructure as a strategic asset and those still constrained by incomplete systems and manual workarounds (FIGURE 2).
Leaders invest in fit-for-purpose technology. They integrate systems across their workflows. They prioritize ownership and interoperability. The result is measurable: faster startup, improved staff productivity, and stronger financial performance. Late adopters, by contrast, remain caught in hybrid environments, part digital and part manual, where inefficiencies compound.
We cannot let fear of increasing burden prevent us from crossing the digital chasm.
The path forward is clear. For years, technology usage was dictated by sponsors and CROs with limited consideration for site infrastructure or operational impact. And while there has been measurable progress toward greater flexibility in technology decisions, sponsors carry a new responsibility to create a digital mandate that is flexible by design.
Sites, in turn, must recognize that maintaining the status quo carries its own cost. Those sites that have crossed the chasm do not reject sponsor-provided technology (FIGURE 3). Instead, they prioritize flexibility and the ability to choose systems that align with their workflows.
Both sites and sponsors must create a digital infrastructure that moves trials forward regardless of where a site sits on the technology maturity curve. In this case, sponsors can provide technologies that improve site efficiency, while also meeting many neutral sites where they are.
The fear of increasing site burden does not outweigh the benefits achieved by crossing the digital chasm. Real burden isn’t adopting new systems; it’s reconstructing incomplete records during audits, delaying approvals because data can’t be trusted, exhausting teams with parallel workflows, and ultimately slowing patient access to therapies because our systems don’t connect.
Digital transformation in clinical research is no longer optional. Regulatory expectations are evolving. Data complexity is increasing. Patients are waiting.
Reference
- Florence Healthcare. 2026 state of clinical trial technology report. Florence Healthcare; 2026.